GlassScriptPhysician profile
Lawrence A Schachner
NPI 1063476653
$308,770.04
in general payments reported to CMS, 2019-2025
27 companies · $8,468 in 2025
The $8,468 reported for 2025 was more than what 92% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177K · 2020: $21K · 2021: $38K · 2022: $22K · 2023: $8,608 · 2024: $33K · 2025: $8,468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $36K · Honoraria: $7,450 · Food and Beverage: $3,484 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,696 · Travel and Lodging: $590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $35,815.00 |
| Honoraria | $7,450.00 |
| Food and Beverage | $3,484.24 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,696.00 |
| Travel and Lodging | $589.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $119,970.45 | 2019-2025 | Seysara |
| Pfizer INC. | $60,667.46 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $33,559.67 | 2019-2023 | Dupixent |
| Dermavant Sciences, INC. | $32,085.70 | 2023-2024 | Vtama |
| Genzyme Corporation | $17,137.31 | 2019-2022 | |
| Nobelpharma America, LLC | $9,747.69 | 2022-2024 | |
| Biofrontera INC. | $7,538.31 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $7,068.44 | 2020-2023 | |
| Pierre Fabre Pharmaceuticals, INC. | $5,393.32 | 2019-2021 | |
| Lnhc, INC | $4,550.10 | 2025 | Zelsuvmi |
| Abeona Therapeutics, INC. | $3,097.60 | 2025 | Zevaskyn |
| Verrica Pharmaceuticals INC. | $2,351.03 | 2023-2025 | Ycanth |
| Arcutis Biotherapeutics, INC. | $2,175.75 | 2023-2025 | Zoryve |
| Amryt Pharma Holdings LTD | $1,300.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $575.92 | 2021-2023 | Sotyktu |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $375.30 | 2024 | Otezla |
| Incyte Corporation | $318.72 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $302.25 | 2021-2025 | Anzupgo |
| Abbvie INC. | $203.98 | 2020-2024 | |
| Intuitive Surgical, INC. | $155.21 | 2019 | |
| Lilly USA, LLC | $124.74 | 2021 | |
| Regeneron Pharmaceuticals, INC. | $32.13 | 2022 | |
| Janssen Scientific Affairs, LLC | $30.46 | 2021 | |
| Sanofi-Aventis U.S. LLC | $7.00 | 2019 | |
| Organon LLC | $1.50 | 2025 | Vtama |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Schachner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.